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Aortic valve calcification and mechanical stenosis is a common finding in advanced age and has a progressive course. Myocardial dysfunction and remodeling, on the other hand, is a common entity in advanced age and could be caused by a wide variety of sources (from a mechanical sequel of valvular diseases, to coronary artery disease, hypertension, diastolic dysfunction, and a host of cardiomyopathies). The overlap of these 2 interdependent entities, in the growing population of elderly patients, is a source of complexity in our daily practice as their presenting symptoms, namely dyspnea, are very nonspecific. Unfortunately, our knowledge of these mechanical/hemodynamic enigmas appears to exceed our insight into the molecular science of myocardial cells.

Over the past 10 years, with improvement in interventional skills, prosthetic valve fabrication, and multimodality imaging, transcatheter aortic valve replacement (TAVR) has evolved to become almost a routine procedure in our daily clinical practice. Indeed, one might note that never in the history of cardiology has a procedure gone from "gee whiz" to "ho hum" so quickly! A myriad of high‐quality randomized clinical trials have targeted patients with decreasing operative risk, from inoperable to high‐risk to intermediate risk, with current trials seeking to extend the safety profile essentially to all patients with trileaflet calcific aortic stenosis (AS). Guidelines from American and European Societies have recognized the utility of TAVR in growing segments of patients with AS.[1](#jah33151-bib-0001){ref-type="ref"}, [2](#jah33151-bib-0002){ref-type="ref"}

Severity of AS must be viewed as a continuum: from aortic sclerosis to hemodynamically severe valve obstruction. The 2017 focused update on the echocardiographic assessment of AS by the European Association of Cardiovascular Imaging and the American Society of Echocardiography[3](#jah33151-bib-0003){ref-type="ref"} provided new insights into the difficult subgroup with low‐gradient AS, and recommended a systematic stepwise approach for accurate AS evaluation.

AS grading can be straightforward when the maximum velocity, mean pressure gradient (MPG), and aortic valve area (AVA) are all concordant. When these parameters are discordant, it is important to integrate these criteria with additional imaging findings plus clinical data to determine the final diagnosis. This is especially important when the MPG suggests only moderate AS and the AVA by continuity equation falls in the severe range ([Figure](#jah33151-fig-0001){ref-type="fig"}).

![Stepwise approach to the complex subgroup of low gradient aortic stenosis (AS). Top panel: Disconnect between aortic valve area (AVA) and peak velocity and mean gradient in current guidelines definitions of severe AS. Fluid dynamic principles indicate that a mean gradient of 40 mm Hg or greater would be associated with an AVA of 0.8 cm^2^. The threshold of 1.0 cm^2^ is more aligned with moderate AS. Bottom panel: Decision tree for management decisions based on flow status determined by stroke volume index (SVI). BP indicates blood pressure; LFLG, low‐flow low‐gradient; CR, contractile reserve; DSE, dobutamine stress echocardiography; GLS, global longitudinal strain; HTN, hypertension; LV, left ventricle; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; MDCT, multidetector computed tomography; R/o, rule out; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; TAVR‐UNLOAD, transcatheter aortic valve replacement to unload the left ventricle in patients with advanced heart failure.](JAH3-7-e008932-g001){#jah33151-fig-0001}

A systematic approach must be adopted, with special attention to any confounding factors that could distort the patient\'s underlying hemodynamic condition; these include the volume status and blood pressure at the time of study, presence of severe anemia, fever, or high‐flow states such as aortic insufficiency and thyrotoxicosis. Accurate Doppler interrogation of maximum velocity and MPG along with detailed measurement of left ventricular (LV) outflow tract diameter is necessary for calculating AVA by continuity equation. This underscores the need for an accredited echocardiography laboratory for daily clinical practice and core laboratories for clinical trials.

It should also be noted that current thresholds for AVA and velocity/gradient for defining severe AS are not consistent. Based on fluid dynamics principles, to generate a mean gradient of 40 mm Hg at a normal flow rate in a standard‐sized human, the projected valve area must be closer to 0.8 than to 1.0 cm^2^.[4](#jah33151-bib-0004){ref-type="ref"}, [5](#jah33151-bib-0005){ref-type="ref"}, [6](#jah33151-bib-0006){ref-type="ref"} On the other hand, determination of the flow status by stroke volume index (SVI) has intrinsic limitations. With increasing severity of AS the ejection time may prolong, and even patients with a normal SVI may have reduced transvalvular flow.[7](#jah33151-bib-0007){ref-type="ref"} These caveats must be taken into account when measures of AS severity are conflicting.

In this issue of the *Journal of the American Heart Association* (*JAHA*), Mangner and colleagues investigate the impact of SVI, MPG, and LV ejection fraction (LVEF) on mortality and functional capacity in a single‐center cohort of 1600 patients who underwent TAVR from 2006 to 2014.[8](#jah33151-bib-0008){ref-type="ref"}

Patients undergoing TAVR in this study were all symptomatic and considered to have severe AS, although it is not clear whether this was based on AVA or MPG or a combination of both. Approximately half of the patients had normal flow (NF) using a threshold of SVI \>35 mL/m^2^. Patients were subgrouped according to NF versus low‐flow (LF) and high versus low MPG (high gradient \>40 mm Hg). Patients with LF and low gradient (LG) were further subdivided into those with classical LF‐LG AS (LVEF ≤50%) and paradoxical LF‐LG AS (LVEF \>50%). The authors noted that patients with LF AS (comprising ≈50% of patients) had higher 30‐day and 3‐year all‐cause mortality rates, independent of MPG and LVEF. These are important observations. It is noteworthy, however, that patients in the 3 LF groups had a greater burden of comorbid conditions than those with NF AS, with higher Society of Thoracic Surgeons scores and logistic EuroScores, greater New York Heart Association functional class, and higher levels of N‐terminal pro‐brain natriuretic peptide. As the patients with LF were clearly a sicker group than those with NF, there is undoubtedly the potential for unmeasured confounding that would contribute to the worse outcomes in the LF groups.

It is also worth noting that not all patients in this series may have had truly severe AS. First, those with NF‐LG and normal LVEF (18% of all patients) may not have had severe AS if an AVA threshold of 1.0 cm^2^ was used rather than 0.8 cm^2^, as noted above. The 2017 focused guideline update[1](#jah33151-bib-0001){ref-type="ref"} emphasized that these patients should *not* be categorized as severe AS ([Figure](#jah33151-fig-0001){ref-type="fig"}), a recommendation supported by studies demonstrating similar outcome of such patients and those with moderate AS.[9](#jah33151-bib-0009){ref-type="ref"}, [10](#jah33151-bib-0010){ref-type="ref"}

Second, among patients in the classical LF‐LG group (14% of the total), the absence of dobutamine stress data, as noted by the authors, leaves open the possibility that some may have had only moderate AS[11](#jah33151-bib-0011){ref-type="ref"} and symptoms could have been driven by primary LV dysfunction. Whether TAVR improves outcomes in such patients is being tested in the ongoing TAVR‐UNLOAD randomized trial (Transcatheter Aortic Valve Replacement to Unload the Left Ventricle in Patients With Advanced Heart Failure; NCT02661451).

Third, the patients with paradoxical LF‐LG AS with normal LVEF (11% of patients) represent an enigmatic group in which the confirmation of severe AS remains elusive.[12](#jah33151-bib-0012){ref-type="ref"} In the absence of confirmatory data, such as aortic valve calcification determined by computed tomography, it is possible that several of these patients may have had a phenotype of heart failure with preserved EF more so than severe AS, which might explain lack of benefit of TAVR.

Numerous large clinical trials and registry cohort studies have reported the influence of MPG,[13](#jah33151-bib-0013){ref-type="ref"} LVEF,[14](#jah33151-bib-0014){ref-type="ref"} and flow,[15](#jah33151-bib-0015){ref-type="ref"}, [16](#jah33151-bib-0016){ref-type="ref"}, [17](#jah33151-bib-0017){ref-type="ref"} and some a combination of 2 or all 3 factors, on outcomes of patients after TAVR, but with no consistent unifying results. A common message of these studies appears to be that LVEF is a strong predictor of outcomes in patients undergoing surgical valve replacement, while MPG and flow are powerful risk factors for mortality in patients undergoing TAVR.[18](#jah33151-bib-0018){ref-type="ref"}, [19](#jah33151-bib-0019){ref-type="ref"}, [20](#jah33151-bib-0020){ref-type="ref"}

One very salutary aspect of the study of Mangner et al is the independent assessment of the optimal cut point for SVI that is associated with mortality,[8](#jah33151-bib-0008){ref-type="ref"} which they determined to be 34.4 mL/m^2^, gratifyingly close to the traditionally used value of 35 mL/m^2^. Their observation that LF status, itself, rather than the mechanism leading to LF, is significantly associated with short‐term and long‐term mortality after TAVR is an important take‐home message, but one that is tempered by the likelihood of residual confounding noted previously.

These data should stimulate further research to unravel the complex inter‐relationships between LV function, pressure gradient, and flow in patients with AS and how these hemodynamic factors relate to prognosis. Conceivably such information could in the future inform decisions regarding whether TAVR or other interventions will be efficacious or futile. However, these factors should never be considered in isolation of the full clinical presentation of individual patients and need to be integrated with clinical factors that are more difficult to measure, such as symptoms and the impact of comorbid conditions and frailty. As we refine our diagnostic tools to identify those with truly severe AS, we must also improve our knowledge of the clinical characteristics that identify patients in whom TAVR will lead to improved survival and enhanced quality of life.
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